Lung Cancer

Lung Cancer Isotype

Non-Small Cell Lung Cancer

Squamous Cell Carcinoma

Adenocarcinoma

Large-Cell Lung Carcinoma

Small-Cell Lung Cancer

Small-Cell Lung Cancer

Chemotherapy

Platinum-based

Nedaplatin

Cisplatin

Carboplatin

Lobaplatin

Alkaloids

Nab-Paclitaxel

Vinorelbine ditartrate

Paclitaxel

Docetaxel

Antimetabolites

Pemetrexed

Gemcitabine

Methotrexate

TOPO Inhibitors

Irinotecan

Etoposide

Topotecan

Doxorubicin

Alkylating Agents

TMZ

Ifosfamide

Cyclophosphamide

Immune Checkpoint Inhibitors

PD-1

Cemiplimab

Pembrolizumab

Camrelizumab

Sintilimab

Nivolumab

Serplulimab

PD-L1

Avelumab

Atezolizumab

Durvalumab

Adebrelimab

Sugemalimab

Cosibelimab

CTLA-4

Ipilimumab

Tremelimumab

KRAS G12C-Targeted

ADC

c-Met

Telisotuzumab vedotin

HER3

Patritumab deruxtecan

HER2

Trastuzumab-deruxtecan

Trastuzumab-Emtansine

TROP2

Sacituzumab-govitecan

Datopotamab deruxtecan

EGFR

Cetuximab-MMAE

ALK

MS4078

CEACAM5

Tusamitamab ravtansine

ROR2

Ozuriftamab vedotin

HER2-Targeted

Pan-HER TKIs

Afatinib

Neratinib

Dacomitinib

Selective HER2 TKIs

Pyrotinib dimaleate

Poziotinib

Sunvozertinib

Anti-HER2 Antibodies

Trastuzumab

Pertuzumab

ALK-Targeted

First-Generation ALK-TKIs ^[1]

Crizotinib

Second-Generation ALK-TKIs ^[1]

Ceritinib

Alectinib

Brigatinib

Ensartinib dihydrochloride

Third-Generation ALK-TKIs ^[1]

Lorlatinib 

EGFR-Targeted

First-Generation EGFR-TKIs ^[2]

Erlotinib

Gefitinib

Lapatinib

Icotinib

Second-Generation EGFR-TKIs ^[2]

Afatinib

Dacomitinib

Neratinib

Poziotinib

Third-Generation EGFR-TKIs ^{[3] [4]}

Osimertinib

Mobocertinib

Rociletinib

Olmutinib

Nazartinib

Alflutinib mesylate

Almonertinib

Lazertinib

Fourth-Generation EGFR-TKIs ^[3]

EAI045

BLU-945

CH7233163

TQB3804

Anti-EGFR Antibodies

Cetuximab

Panitumumab

Necitumumab

Anti-Angiogenesis

MET-Targeted

Type I MET-TKIs ^[5]

Crizotinib

Capmatinib

Tepotinib

Savolitinib

Type II MET-TKIs ^[5]

Cabozantinib

Merestinib

Type III MET-TKIs ^[5]

Tivantinib

ROS1-Targeted

First-Generation ROS1-TKIs ^[6]

Crizotinib

Second-Generation ROS1-TKIs ^[6]

Ceritinib

Repotrectinib

Third-Generation ROS1-TKIs ^[6]

Lorlatinib 

BRAF-Targeted

First-Generation (Type I) BRAF Inhibitors ^[7]

Vemurafenib

Dabrafenib

Encorafenib

Next-Generation (Type II) BRAF Inhibitors ^[7]

AZ 628

LY3009120

Belvarafenib

CCT196969

Tovorafenib

Naporafenib

PLX7904

Plixorafenib

RET-Targeted

Selective RET Inhibitors

Selpercatinib

Pralsetinib

Non-Selective RET Inhibitors

Cabozantinib

Vandetanib

Lenvatinib

Regorafenib

Compound Library